Molecular diagnostics company Agendia (Amsterdam, The Netherlands and Huntington Beach, Calif.) has opened a CLIA-licensed clinical genomics laboratory in Huntington Beach. The facility will perform the company's molecular diagnostic tests for cancer, including MammaPrint, which predicts the risk of breast cancer recurrence and in 2007 became the first in vitro diagnostic multivariate index assay (IVDMIA) to be cleared by the U.S. Food and Drug Administration. Agendia also has a clinical laboratory at its Amsterdam headquarters.

"Our new genomics lab's capacity will allow us to meet the increasing demand for MammaPrint across the United States and give physicians and patients optimal test result turnaround and unmatched service and support," said Jan Groen, Ph.D., Agendia's chief operating officer, in a statement issued by the company.

Pathologist Chynel Henning, M.D., will serve as laboratory director. Other recent hires at Agendia's U.S. office include Chief Medical Officer Richard Bender, M.D.; Daniel Forche, vice president of sales and marketing; and Alan B. Carter, vice president of global business development.